New research has found that the cell and gene therapy clinical environment in the UK has encouraged commercial sponsorship from around the world.
List view / Grid view
Victoria Rees (European Pharmaceutical Review)
Filter the results
A survey has found that a large portion of healthcare organisations in the UK experienced cyber-security incidents last year, which were mostly due to employees sharing data.
An inspection at a manufacturing facility belonging to Health Pharma has revealed breaches of cGMP regulations, causing the FDA to send a warning letter.
The Japanese Ministry of Health, Labour and Welfare (#MHLW) has granted marketing approval for Dovato, a treatment for HIV-1 infection.
The US FDA has announced a warning to healthcare professionals and patients that the weight management drug Belviq may be a cause of cancer.
Jasper Ojela, a registered pharmacist who admitted to supplying the black market with drugs including cancer medications, has been given a 28-month prison sentence.
A new ‘green plastic’ alternative that degrades in 10 years has been created, which can be used in the pharmaceutical packaging industry.
The US state of Oklahoma has agreed to a settlement from Endo International after an investigation into its role in the opioid abuse crisis.
According to new research, M&As within the life science industry reached a high last year and is expected to continue its growth in 2020.
A partnership between Novartis and NHS England includes a proposal to investigate processes that can increase the scale and efficacy of oligonucleotide manufacture.
Due to cross-contamination with enalapril maleate, Taro is voluntarily recalling one lot of its lamotrigine tablets at the consumer level.
According to Eli Lilly, the company will acquire Dermira in an all-cash transaction for $1.1 billion, at a rate of $18.75 per share.
A study has revealed that in 2018, almost half of the spending on brand medicines went to the supply chain and other entities in the US.
In a bid to lower the costs of medicines, California's governor has suggested contracting generic drug manufacturers to make pharmaceutical products for the state to sell, according to reports.